Rigel Pharmaceuticals
Yahoo Finance • last year
Rigel to Present at the Jefferies London Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Dean Schorno, the company's chief financial officer, will present a company overview at the Jefferies 2023 London Hea... Full story
Yahoo Finance • last year
Investors in Rigel Pharmaceuticals (NASDAQ:RIGL) have unfortunately lost 55% over the last five years
We think intelligent long term investing is the way to go. But no-one is immune from buying too high. Zooming in on an example, the Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) share price dropped 55% in the last half decade. We certainly fee... Full story
Yahoo Finance • 2 years ago
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., April 6, 2023 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compens... Full story
Yahoo Finance • 2 years ago
Rigel Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Fourth quarter 2022 Total Revenue of $51.3 million which includes TAVALISSE® net product sales of $21.9 million and REZLIDHIA™ net product sales of $0.9 million REZLIDHIA U.S. commercial launch continues to progress and is supported by rec... Full story
Yahoo Finance • 2 years ago
Rigel Doses First Patient in Phase 1b Study of R289 for the Treatment of Lower-Risk Myelodysplastic Syndromes
R289 is an investigational, oral, inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), being studied as a potentially differentiated approach to treating lower-risk MDS SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 /PRNews... Full story
Yahoo Finance • 2 years ago
Increasing losses over year doesn't faze investors as stock surges 10% this past week
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) shareholders will doubtless be very grateful to see the share price up 97% in the last month. But that doesn't change the fact that the returns over the last year have been disappointing. During th... Full story
Yahoo Finance • 2 years ago
Rigel Announces Top-line Results from FORWARD Phase 3 Clinical Trial of Fostamatinib in Patients with Warm Autoimmune Hemolytic Anemia
Conference call and webcast to be held today at 8:00 a.m. Eastern Time SOUTH SAN FRANCISCO, Calif., June 8, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced top-line efficacy and safety data from the FORWARD... Full story
